During the last session, Atyr Pharma Inc (NASDAQ:ATYR)’s traded shares were 1.45 million, with the beta value of the company hitting 1.21. At the end of the trading day, the stock’s price was $1.82, reflecting an intraday loss of -1.09% or -$0.02. The 52-week high for the ATYR share is $2.50, that puts it down -37.36 from that peak though still a striking 40.66% gain since the share price plummeted to a 52-week low of $1.08. The company’s market capitalization is $137.96M, and the average intraday trading volume over the past 10 days was 0.48 million shares, and the average trade volume was 375.95K shares over the past three months.
Atyr Pharma Inc (NASDAQ:ATYR) trade information
Atyr Pharma Inc (ATYR) registered a -1.09% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.09% in intraday trading to $1.82, hitting a weekly high. The stock’s 5-day price performance is -3.70%, and it has moved by -3.70% in 30 days. Based on these gigs, the overall price performance for the year is 13.04%. The short interest in Atyr Pharma Inc (NASDAQ:ATYR) is 0.44 million shares and it means that shorts have 1.47 day(s) to cover.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Atyr Pharma Inc (ATYR) estimates and forecasts
Statistics show that Atyr Pharma Inc has underperformed its competitors in share price, compared to the industry in which it operates. Atyr Pharma Inc (ATYR) shares have gone down -9.00% during the last six months, with a year-to-date growth rate less than the industry average at 3.19% against 17.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -10.00% this quarter and then jump 12.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -17.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 20k as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 20k by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 43.36%. While earnings are projected to return 6.21% in 2024, the next five years will return 13.00% per annum.
ATYR Dividends
Atyr Pharma Inc is due to release its next quarterly earnings in October. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
